Last updated: May 25, 2026
Adapalene and Benzoyl Peroxide Suppliers: Who Makes the APIs and Key Formulation Ingredients?
Adapalene and benzoyl peroxide are sourced through two supply layers: (1) active pharmaceutical ingredient (API) manufacturers and (2) excipient and formulation ingredient suppliers that support fixed-dose combinations (FDCs), gels, creams, and topical oxidant systems. Supplier selection is typically driven by regulatory status (DMF/CEP availability), particle control for topical uniformity, and compatibility with oxidizers (for benzoyl peroxide) under shelf-life constraints.
What this matters for: procurement, contract manufacturing (CMO/CDMO) qualification, and IP-safe sourcing for branded FDCs and generic/topical entrants.
Who are the major API suppliers for adapalene?
Adapalene (a topical retinoid) is primarily supplied as the API or as an intermediate package through chemical synthesis routes scaled in Asia and Europe. For topical drug products, the critical supplier attributes are consistent impurity profiles, polymorphic/solid-state control, and particle size distribution suited to gel and cream processing.
What credentials do adapalene API suppliers typically offer?
- DMF or ASMF support for US dossiers (Type II/III filings depending on structure and supply chain)
- CEP for European registration support (where applicable)
- Impurity and genotoxic impurity controls aligned to ICH expectations for dermatology actives
How to screen adapalene API suppliers for topical product readiness
- Lot-to-lot variability in assay and impurities
- Stability under formulation conditions (light sensitivity and oxidation-relevant conditions, depending on excipient selection)
- Compatibility with Carbopol/crosslinked polymer systems and emulsions used in gels and creams
Procurement note: In practice, most commercial supply comes from a small number of large API houses plus specialty manufacturers that can meet gel-formulation particle specs.
Who are the major API suppliers for benzoyl peroxide?
Benzoyl peroxide is an oxidizing agent supplied in multiple commercial grades and particle forms. The supplier landscape is shaped by safety regulations for oxidizers, packaging requirements, and stabilization controls that preserve peroxide content.
What credentials do benzoyl peroxide suppliers typically offer?
- Defined concentration grade (for example, standard powders or standardized dispersions, depending on market)
- Safety documentation for transport and storage
- Quality documentation that tracks peroxide content over time and under temperature cycling
How supplier grade affects formulation outcomes
- Particle size and wetting behavior influence peroxide dispersion uniformity in gels/creams
- Stabilizer and impurity profile affect skin tolerance and shelf-life
- Compatibility with cationic/anionic polymer systems used for topical products
Which companies supply fixed-dose combination formulations of adapalene and benzoyl peroxide?
For the combination market, product manufacturing is usually done by specialty dermatology CMOs/CDMOs, while APIs are purchased from upstream API suppliers. Fixed-dose topical products require formulation that prevents benzoyl peroxide instability and maintains adapalene potency.
Formulation constraints that drive supplier selection
- Benzoyl peroxide can degrade under heat and in incompatible packaging ecosystems
- Adapalene stability is sensitive to processing conditions and light exposure
- Both actives require tight controls for uniformity and content uniformity in semi-solid dosage forms
What patents affect supply chain options for adapalene + benzoyl peroxide products?
Patent risk mostly concerns:
- the specific combination formulation (if claimed)
- manufacturing process steps that stabilize benzoyl peroxide with particular polymer systems or emulsions
- method-of-use claims (often less relevant for supplier sourcing unless directly tied to dosing instructions)
Actionable sourcing implication: even if API is available, a manufacturer still needs freedom-to-operate at the product and process level for the exact dosage form and strength.
What Orange Book and patent listings typically determine US supplier and CMO eligibility?
For US commercialization, the controlling documents are:
- Orange Book listings for the branded/reference product
- Orange Book expiration and any listed patents tied to the drug product, formulation, or use
- Whether a generic/topical applicant has submitted a paragraph IV or other certification strategy
Actionable implication for suppliers: if a CMO’s process is optimized for a specific protected formulation, onboarding a different supplier grade of API or peroxide particle system can trigger reformulation and, in turn, new validation and IP review.
When do adapalene and benzoyl peroxide topical exclusivities expire?
Exclusivity and patent expiry timing depends on the specific reference drug and NDA/ANDA entry for the combined product (or separate products). Without the exact marketed product identifiers (NDA/ANDA holders, label strengths, and dosage form), exact expiry dates cannot be stated reliably.
What formulation ingredient suppliers matter most for adapalene + benzoyl peroxide gels?
Most supply bottlenecks sit in formulation “platform” components rather than only the two actives.
Key excipient categories commonly involved
- Polymeric gelling agents and thickeners (gel viscosity and spreadability)
- Surfactants/emulsifiers (cream stability, wetting, and peroxide dispersion)
- Preservatives and pH adjusters (stability and skin tolerability)
- Antioxidants and light-protection systems where used (product-specific)
- Packaging system components compatible with peroxide oxidizers
Packaging supplier relevance
Benzoyl peroxide needs packaging and closure systems with proven compatibility. Suppliers of:
- tube materials
- liners
- closures
- secondary packaging that blocks light
can drive feasibility and stability qualification timelines.
How does benzoyl peroxide oxidizer compatibility affect CMO supplier qualification?
Compatibility is a qualification gate. CMOs typically require:
- peroxide grade validation (content assay before and after manufacturing steps)
- container closure integrity compatibility studies
- accelerated stability data for strength and uniformity
Operational implication: suppliers can be “approved” for chemistry but rejected for peroxide performance in specific manufacturing workflows.
Which manufacturing and scale-up risks affect API and oxidizer supply for topical combination products?
Topical scale-up is sensitive to:
- peroxide dispersion uniformity during high-shear steps
- temperature profiles during compounding and filling
- filtration and batching decisions that can change particle distributions
- mixing order and hold times (oxidizer systems are more time-temperature sensitive)
Key Takeaways
- Adapalene and benzoyl peroxide supply typically splits into upstream API oxidizer suppliers and downstream dermatology formulation/packaging suppliers used by CMO/CDMOs.
- Procurement success depends less on “API availability” and more on quality documentation, impurity control, oxidizer grade and peroxide content tracking, and packaging compatibility.
- Fixed-dose combination feasibility hinges on peroxide stability and dispersion engineering, which can force reformulation if API/oxidizer grades change.
FAQs
1) Can I use any benzoyl peroxide grade in an adapalene fixed-dose topical gel?
Not reliably. Benzoyl peroxide grade and particle characteristics drive dispersion, peroxide content retention, and shelf-life performance.
2) Are adapalene and benzoyl peroxide supplied only as pure APIs?
They can be supplied as APIs/grades of peroxide optimized for specific formulation needs, but peroxide is often supplied with standardized control parameters tied to concentration and stability.
3) What matters more for topical uniformity: API particle size or excipient gelling agent?
Both. API particle behavior affects dispersion and uniformity, while gelling agent systems control spreadability and prevent phase separation that can concentrate peroxide.
4) Who typically manufactures the final adapalene + benzoyl peroxide drug product?
Usually a dermatology-focused CMO/CDMO that already has a peroxide-compatible formulation and packaging workflow.
5) How do patent restrictions influence sourcing decisions for APIs?
They can force changes to formulation or manufacturing process design, which then requires requalification of API/grade choices and excipient systems.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ICH. (2006). ICH Q3A(R2): Impurities in New Drug Substances. International Council for Harmonisation.
- ICH. (2008). ICH Q3B(R2): Impurities in New Drug Products. International Council for Harmonisation.
- ICH. (2009). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. International Council for Harmonisation.
